newsfilter
← Latest News
Business Wire·

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate